# PREDATOR: Neoadjuvant Gene Prediction for Breast Cancer

> **NCT02067416** · PHASE2 · WITHDRAWN · sponsor: **Jenny C. Chang, MD**

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Anthracycline based chemotherapy
- **DRUG:** taxane-based chemotherapy

## Key facts

- **NCT ID:** NCT02067416
- **Lead sponsor:** Jenny C. Chang, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2012-07
- **Primary completion:** 2014-06
- **Final completion:** 2014-06
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Funding agent withdrew funding
- **Last updated:** 2023-02-02

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02067416

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02067416, "PREDATOR: Neoadjuvant Gene Prediction for Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02067416. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*